Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SYK
stocks logo

SYK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.12B
+10.61%
4.392
+9.52%
6.32B
+7.74%
3.063
+7.86%
6.54B
+8.64%
3.477
+11.1%
Estimates Revision
The market is revising Upward the revenue expectations for Stryker Corporation (SYK) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -7.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.4%
In Past 3 Month
Stock Price
Go Down
down Image
-7.61%
In Past 3 Month
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 432.38 USD with a low forecast of 400.00 USD and a high forecast of 456.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 432.38 USD with a low forecast of 400.00 USD and a high forecast of 456.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
3 Hold
0 Sell
Strong Buy
Current: 364.350
sliders
Low
400.00
Averages
432.38
High
456.00
Current: 364.350
sliders
Low
400.00
Averages
432.38
High
456.00
Truist
Richard Newitter
Hold
maintain
$392 -> $400
2025-11-14
Reason
Truist
Richard Newitter
Price Target
$392 -> $400
2025-11-14
maintain
Hold
Reason
Truist analyst Richard Newitter raised the firm's price target on Stryker to $400 from $392 and keeps a Hold rating on the shares. The company's Investor Day showcased why Stryker should remain one of the higher quality large-cap MedTechs with "muscle" and continue delivering annual operating leverage, the analyst tells investors in a research note. Truist adds however that it remains in neutral as the firm prefers large-caps with faster earnings and revenue growth profiles.
Wells Fargo
Overweight
maintain
$452 -> $456
2025-11-14
Reason
Wells Fargo
Price Target
$452 -> $456
2025-11-14
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Stryker to $456 from $452 and keeps an Overweight rating on the shares. The firm notes the company's 2025 investor meeting highlighted the potential for sustained 10% organic topline growth and double-digit EPS growth. Margin target of 150bps next 3 years was slightly better than expected. Key pipeline updates include Mako RPS hand-held robot, Wells adds.
BTIG
BTIG
Buy
downgrade
$122 -> $112
2025-11-05
Reason
BTIG
BTIG
Price Target
$122 -> $112
2025-11-05
downgrade
Buy
Reason
BTIG lowered the firm's price target on Zimmer Biomet (ZBH) to $112 from $122 and keeps a Buy rating on the shares following disappointing Q3 results. The firm notes that relative to peers, Zimmer Knee growth fell below Stryker (SYK) but above Johnson & Johnson (JNJ) while Hips were softest among the 3. There is no way to spin it, results were disappointing relative to expectations as Zimmer came off a strong Q2 and into the print investor enthusiasm was growing from an easier comp and new product launches, says BTIG.
Truist
Hold
downgrade
$407 -> $392
2025-11-03
Reason
Truist
Price Target
$407 -> $392
2025-11-03
downgrade
Hold
Reason
Truist lowered the firm's price target on Stryker to $392 from $407 and keeps a Hold rating on the shares. The company delivered a small revenue beat with mixed quality earnings upside that was driven by non-op items and tax, which offset a slight operating margin miss, the analyst tells investors in a research note.
Evercore ISI
Outperform
maintain
$410 -> $405
2025-10-31
Reason
Evercore ISI
Price Target
$410 -> $405
2025-10-31
maintain
Outperform
Reason
Evercore ISI lowered the firm's price target on Stryker to $405 from $410 and keeps an Outperform rating on the shares. Stryker's Q3 performance was solid with a 9.5% organic growth, slightly topping Wall Street estimates, mainly driven by Orthopedics' strong showing, the analyst tells investors in a research note. The firm noted that MedSurg and NeuroTech held steady, though Endoscopy and Medical lagged a bit behind expectations.
Truist
Richard Newitter
Hold
downgrade
$407 -> $392
2025-10-31
Reason
Truist
Richard Newitter
Price Target
$407 -> $392
2025-10-31
downgrade
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on Stryker to $392 from $407 and keeps a Hold rating on the shares following Q3 results with "mixed quality" earnings upside. Some key organizational revenue drivers fell short, but hips/knees picked up and record Mako placements could be suggestive of Mako 4 gaining steam, Truist told investors in a research note. The firm's estimates inch upwards, and with the November 13 investor day coming up, Truist said it will get a sense of management's long-term targets and whether there could be faster growth prospects to support a higher multiple.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Stryker Corp (SYK.N) is 25.13, compared to its 5-year average forward P/E of 26.33. For a more detailed relative valuation and DCF analysis to assess Stryker Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
26.33
Current PE
25.13
Overvalued PE
28.45
Undervalued PE
24.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
21.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
22.88
Undervalued EV/EBITDA
19.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.35
Current PS
0.00
Overvalued PS
5.85
Undervalued PS
4.85
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 143.32% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 119.77% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 143.32% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SYK News & Events

Events Timeline

(ET)
2025-12-04
08:40:00
Stryker Appoints Spencer Stiles as President and COO
select
2025-10-30 (ET)
2025-10-30
16:13:49
Stryker projects FY25 adjusted EPS between $13.50 and $13.60, surpassing consensus of $13.49
select
2025-10-30
16:13:09
Stryker announces Q3 adjusted earnings per share of $3.19, surpassing consensus estimate of $3.13.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04NASDAQ.COM
Stryker Names Spencer Stiles as President and Chief Operating Officer

  • Appointment Announcement: Stryker Corp. has appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026.

  • Stiles' Experience: Stiles has been with Stryker for 27 years, holding various leadership roles in Orthopaedics, MedSurg, and Neurotechnology, as well as overseeing international operations.

  • CEO's Statement: Kevin Lobo, Chair and CEO of Stryker, stated that Stiles' appointment will enhance the company's growth and leverage its diverse portfolio.

  • Stock Performance: In pre-market trading, Stryker's stock (SYK) is up 0.30 percent, trading at $367 on the New York Stock Exchange.

[object Object]
Preview
7.0
12-04NASDAQ.COM
Tariff Pressures on Margins: Could ISRG's Profitability Be Threatened?

  • Intuitive Surgical's Performance: Intuitive Surgical (ISRG) reported a strong third-quarter with 23% revenue growth and 30% earnings growth, but faced margin pressure due to tariffs and a less favorable cost mix, leading to a pro forma gross margin decline to 68%.

  • Future Margin Outlook: Management has raised its gross-margin outlook for 2025 to 67–67.5%, citing improved cost reductions and a smaller tariff impact, although fourth-quarter margins are expected to dip slightly below 67%.

  • Medtronic's Challenges: Medtronic (MDT) experienced revenue and earnings growth but is also facing profitability pressures from tariffs, with a projected $185 million in tariff costs for the fiscal year, despite operational gross margin improvements.

  • Stryker's Resilience: Stryker (SYK) reported strong growth but noted significant tariff impacts on profitability, emphasizing its ability to manage costs and maintain margins through pricing strategies and operational efficiencies.

[object Object]
Preview
5.0
12-04SeekingAlpha
Stryker Names Spencer Stiles as Chief Operating Officer

  • Leadership Appointment: Spencer Stiles has been appointed as president and COO of Stryker, effective January 1, 2026, where he will oversee global businesses, strategy, and mergers and acquisitions.

  • Stiles' Background: A veteran of Stryker with 27 years of experience, Stiles has held various leadership roles, including Group President of Orthopaedics and Spine since 2019.

  • Successor Announcement: Dylan Crotty will be promoted to succeed Stiles as Group President of Orthopaedics.

  • Company Outlook: Stryker has raised its 2025 outlook to 9.8%-10.2% organic sales growth, indicating strong momentum despite some concerns about valuation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Stryker Corp (SYK) stock price today?

The current price of SYK is 364.35 USD — it has decreased -0.44 % in the last trading day.

arrow icon

What is Stryker Corp (SYK)'s business?

Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.

arrow icon

What is the price predicton of SYK Stock?

Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 432.38 USD with a low forecast of 400.00 USD and a high forecast of 456.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Stryker Corp (SYK)'s revenue for the last quarter?

Stryker Corp revenue for the last quarter amounts to 6.06B USD, increased 10.25 % YoY.

arrow icon

What is Stryker Corp (SYK)'s earnings per share (EPS) for the last quarter?

Stryker Corp. EPS for the last quarter amounts to 2.22 USD, increased 2.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Stryker Corp (SYK)'s fundamentals?

The market is revising Upward the revenue expectations for Stryker Corporation (SYK) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -7.61%.
arrow icon

How many employees does Stryker Corp (SYK). have?

Stryker Corp (SYK) has 53000 emplpoyees as of December 05 2025.

arrow icon

What is Stryker Corp (SYK) market cap?

Today SYK has the market capitalization of 139.34B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free